Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
Medicina (Florence, Italy)
|
April 1, 1988
[Effects on growth hormone secretion of a new somatostatin analogue (SMS 201-995) and nonspecific releasing hormones in patients with acromegaly]
R Candrina
Recenti Progressi in Medicina
|
January 1, 1991
Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration
R Candrina
Diabetes Research and Clinical Practice
|
September 1, 1986
Re: Control of glucose homeostasis in diabetic surgical patients by means of continuous i.v. insulin infusion
R Candrina
Recenti Progressi in Medicina
|
January 1, 1994
Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma
R Candrina
Israel Journal of Medical Sciences
|
January 1, 1988
Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura
R Candrina, A Giustina
JAMA
|
December 5, 1986
Development of acromegaly after pituitary apoplexy
R Candrina, G Giustina
Clinical Endocrinology
|
August 1, 1987
Effects of SMS 201-995 in non-insulin-dependent diabetes
R Candrina, G Giustina
Recenti Progressi in Medicina
|
September 1, 1989
[Treatment of hypophyseal prolactin-secreting macroadenomas]
R Candrina, M Tosoni
The American Journal of the Medical Sciences
|
July 1, 1990
Iodine-induced subacute thyroiditis with thyrotoxicosis presenting as fever of unknown origin
R Candrina, G Giustina
Journal of Endocrinological Investigation
|
July 1, 1988
Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients
R Candrina, G Giustina
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
Medicina (Florence, Italy)
|
April 1, 1988
[Effects on growth hormone secretion of a new somatostatin analogue (SMS 201-995) and nonspecific releasing hormones in patients with acromegaly]
R Candrina
Recenti Progressi in Medicina
|
January 1, 1991
Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration
R Candrina
Diabetes Research and Clinical Practice
|
September 1, 1986
Re: Control of glucose homeostasis in diabetic surgical patients by means of continuous i.v. insulin infusion
R Candrina
Recenti Progressi in Medicina
|
January 1, 1994
Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma
R Candrina
Israel Journal of Medical Sciences
|
January 1, 1988
Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura
R Candrina, A Giustina
JAMA
|
December 5, 1986
Development of acromegaly after pituitary apoplexy
R Candrina, G Giustina
Clinical Endocrinology
|
August 1, 1987
Effects of SMS 201-995 in non-insulin-dependent diabetes
R Candrina, G Giustina
Recenti Progressi in Medicina
|
September 1, 1989
[Treatment of hypophyseal prolactin-secreting macroadenomas]
R Candrina, M Tosoni
The American Journal of the Medical Sciences
|
July 1, 1990
Iodine-induced subacute thyroiditis with thyrotoxicosis presenting as fever of unknown origin
R Candrina, G Giustina
Journal of Endocrinological Investigation
|
July 1, 1988
Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients
R Candrina, G Giustina
Page
of 4